Who Exports Montelukast from India — 510 Suppliers Behind a $168.3M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for the production of active pharmaceutical ingredients (APIs), including Montelukast. The city's pharmaceutical landscape is characterized by a robust infrastructure, a skilled workforce, and a favorable regulatory environment. Companies such as Granules India, headquartered in Hyderabad, exemplify the region's capacity for large-scale API manufacturing. This concentration of API producers ensures a steady supply of Montelukast's raw materials, facilitating both domestic formulation and international export.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts numerous companies specializing in the development and production of finished dosage forms of Montelukast. Alembic Pharmaceuticals, based in Vadodara, is a notable example, contributing significantly to the formulation and export of Montelukast products. The area's emphasis on formulations complements the API production in Hyderabad, creating a seamless supply chain from raw material to finished product.

The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products, including Montelukast. This region's well-developed port infrastructure, particularly the Nhava Sheva Sea Port, facilitates efficient international distribution. Companies operating in this area leverage the logistical advantages to export Montelukast formulations to key markets such as the United States, which accounted for 58.1% of India's Montelukast exports between 2022 and 2026.

The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. This area attracts numerous pharmaceutical companies, contributing to the production of various drugs, including Montelukast. The fiscal benefits and supportive infrastructure make Baddi-Nalagarh an attractive location for cost-effective manufacturing, enhancing the competitiveness of Indian Montelukast in global markets.

• Diversify Supplier Base: Engage with multiple API manufacturers in Hyderabad to mitigate supply chain risks and ensure a consistent supply of Montelukast raw materials.

• Leverage Formulation Expertise: Collaborate with formulation specialists in the Ahmedabad-Vadodara region to develop high-quality Montelukast products tailored to target markets.

• Optimize Export Logistics: Utilize the Mumbai-Thane-Raigad corridor's port facilities to streamline export processes and reduce lead times for international shipments.

• Explore Cost Advantages: Consider manufacturing partnerships in the Baddi-Nalagarh region to benefit from tax incentives and cost efficiencies in Montelukast production.

By strategically engaging with these pharmaceutical clusters, companies can enhance their Montelukast supply chain resilience and capitalize on India's robust pharmaceutical infrastructure.